The 2023 Peer Reviewed Medical Research Program
$370 Million in Non-Dilutive Awards
Start Your Applications for the 2023 PRMRP
Now is the time to begin preparing your applications for the 2023 Peer Reviewed Medical Research Program (PRMRP). The PRMRP is part of CDMRP, the Congressionally Directed Medical Research Program, under the Department of Defense. From 1999 through 2022, Congress appropriated $3.45 billion for PRMRP non-dilutive funding awards. This year alone, it has appropriated $370 million.
PRMRP aims to improve the health, well-being, and care of all military service members, veterans, and beneficiaries, by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit that lead to impactful healthcare advances.
Each application for PRMRP funding must address a Topic Area as directed by the U.S. Congress and have direct relevance to military health. (Other CDMRP awards in additional areas are to be announced. Subscribe to our mailing list, and follow us on LinkedIn so you can stay informed.)
Topic Areas for the 2023 PRMRP
Topic Areas change from year to year. These are the 2023 PRMRP Topic Areas:
- Arthritis
- Celiac Disease
- Dystonia
- Eating Disorders
- Eczema
- Ehlers-Danlos Syndrome
- Endometriosis
- Epidermolysis Bullosa
- Familial Hypercholesterolemia
- Fibrous Dysplasia/McCune-Albright Syndrome
- Focal Segmental Glomerulosclerosis
- Food Allergies
- Fragile X
- Frontotemporal Degeneration
- Guillain-Barre Syndrome
- Hemorrhage Control
- Hepatitis B
- Hereditary Ataxia
- Hydrocephalus
- Hypercholesterolemia
- Inflammatory Bowel Disease
- Interstitial Cystitis
- Lymphatic Disease
- Lymphedema
- Malaria
- Maternal Mental Health
- Mitochondrial Disease
- Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome
- Myotonic Dystrophy
- Nephrotic Syndrome
- Neuroactive Steroids
- Neuroinflammatory Responses to Emerging Viral Diseases
- Non-Opioid Therapy for Pain Management
- Pancreatitis
- Peripheral Neuropathy
- Polycystic Kidney Disease
- Pressure Ulcers
- Proteomics
- Pulmonary Fibrosis
- Respiratory Health
- Rheumatoid Arthritis
- Scleroderma
- Sickle-Cell Disease
- Sleep Disorders and Restriction
- Suicide Prevention
- Trauma
- Tuberculosis
- Vascular Malformations
- Von Hippel-Lindau Syndrome Benign Manifestations
Detailed strategic goals apply for each of the 2023 Topic Areas.
2023 PRMRP Grant Types
The Clinical Trial Awards
The Clinical Trial Awards support the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest. Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
Two options are offered:
- Planning Phase with Clinical Trial Option: Provides support to prepare and submit an Investigational New Drug/ Investigational Device Exemption (IND/ IDE) application to the U.S. Food and Drug Administration (FDA) and requires FDA/regulatory approval or exemption to proceed before the clinical trial may be funded. The maximum allowable funding for the Planning Phase period of performance is $500,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance for the planning phase is 18 months. The maximum period of performance for the clinical trial is 4 years.
- Clinical Trial Only Option: Provides support for the clinical trial. IND or IDE applications to the FDA, if needed, must be approved by the FDA and included in the application submission. A funding limit is not defined; requested funding must be appropriate for the scope of work proposed. The maximum period of performance for the clinical trial is 4 years.
Researchers of Assistant Professor level or above (or equivalent) are eligible.
Preproposal submission is required; application submission is by invitation only.
Pre-Application (Preproposal) deadline: April 12, 2023
Application deadline: July 19, 2023
The Discovery Awards
The Discovery Awards support the exploration of a highly innovative new concept or untested theory. They are not intended to support the logical progression of an already established line of questioning. Clinical trials will not be funded.
The maximum allowable funding for the entire period of performance is $200,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 2 years.
Postdoctoral fellows or clinical fellows (or equivalent) and above are eligible to apply.
Pre-Application (Letter of Intent) deadline: March 29, 2023
Application deadline: April 26, 2023
The Focused Program Awards
The Focused Program Awards support a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question. Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications. Projects may range from exploratory/hypothesis-developing studies through small-scale clinical trials that together will address the overarching goal/question.
The maximum allowable funding for the entire period of performance is $7.2 million for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years.
Full Professors (or equivalent) and above are eligible to apply. The research team of highly qualified, multidisciplinary project leaders should be led by an investigator with demonstrated success in directing large, focused projects.
Preproposal submission is required; application submission is by invitation only.
Pre-Application (Preproposal) deadline: April 12, 2023
Application deadline: July 19, 2023
The Investigator-Initiated Research Awards
The Investigator-Initiated Research Awards support research that will make an original and important contribution to the field of research or patient care in the Topic Area(s) of interest. Clinical trials will not be funded.
The maximum allowable funding for the entire period of performance is $1.6 million for direct costs for single investigators and $2.0 million for partnering investigators. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years.
Assistant Professors (or equivalent) or above are eligible to apply.
Pre-Application (Letter of Intent) deadline: April 19, 2023
Application deadline: May 31, 2023
The Lifestyle and Behavioral Health Interventions Research Awards
The Lifestyle and Behavioral Health Interventions Research Awards support development, evaluation, and implementation of therapies, technologies, and innovations that will enhance patient experience and improve outcomes. Projects may include clinical research or clinical trials for interventions that do not require regulation by the FDA. Animal studies will not be funded.
The maximum allowable funding for the entire period of performance is $3.0 million for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years.
Assistant Professors (or equivalent) or above are eligible to apply. Patient advocates are encouraged on research teams.
Pre-Application (Letter of Intent) deadline: April 19, 2023
Application deadline: May 31, 2023
The Technology/Therapeutic Development Awards
The Technology/Therapeutic Development Awards support the translation of promising preclinical findings into products (e.g., device, drug, clinical guidelines) for prevention, detection, diagnosis, treatment, and/or quality of life. The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. Clinical trials will not be funded.
Two funding levels are available depending on the maturity of the product:
- Funding Level 1: This supports research that is supported by significant preliminary data but has not advanced to the level of clinical translation. The maximum allowable funding for the entire period of performance is $2.0 million for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years.
- Funding Level 2: This supports research that is in the final states of preclinical development with potential for near-term clinical development. Applications must provide relevant data that support the rationale for the proposed study. Funding Level 2 recipients must submit or obtain an IND/IDE application to the FDA, or must transition the product to clinical practice, within the period of performance. The maximum allowable funding for the entire period of performance is $4.0 million for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years.
Assistant Professors (or equivalent) and above are eligible to apply.
Pre-Application (Letter of Intent) deadline: April 19, 2023
Application deadline: May 31, 2023
What Other Unknown Opportunities Are There?
We hope you found an award opportunity here that looks right for you. Whether you did or not, there are probably many other non-dilutive funding opportunities that fit your R&D. Do you know all the opportunities that are right for you?
